4/18
08:17 am
pbla
Panbela Announces Poster Presentation at American Association for Cancer Research: [Yahoo! Finance]
Medium
Report
Panbela Announces Poster Presentation at American Association for Cancer Research: [Yahoo! Finance]
4/18
08:00 am
pbla
Panbela Announces Poster Presentation at American Association for Cancer Research:
Medium
Report
Panbela Announces Poster Presentation at American Association for Cancer Research:
4/16
05:29 pm
pbla
Panbela Announces Transfer to OTCQB Market
Low
Report
Panbela Announces Transfer to OTCQB Market
3/27
12:11 pm
pbla
Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $25.00 price target on the stock.
Medium
Report
Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $25.00 price target on the stock.
3/27
11:04 am
pbla
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/26
04:30 pm
pbla
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results [Yahoo! Finance]
Medium
Report
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results [Yahoo! Finance]
3/26
04:10 pm
pbla
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Medium
Report
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
3/12
04:15 pm
pbla
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Low
Report
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
2/15
08:00 am
pbla
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Medium
Report
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
2/5
02:13 pm
pbla
Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its price target lowered by analysts at Roth Mkm from $500.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its price target lowered by analysts at Roth Mkm from $500.00 to $25.00. They now have a "buy" rating on the stock.
2/1
07:11 am
pbla
Panbela Announces Closing of Approximately $9.0 Million Public Offering [Yahoo! Finance]
Medium
Report
Panbela Announces Closing of Approximately $9.0 Million Public Offering [Yahoo! Finance]
2/1
07:00 am
pbla
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Medium
Report
Panbela Announces Closing of Approximately $9.0 Million Public Offering
1/30
08:15 am
pbla
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Medium
Report
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
1/29
06:15 am
pbla
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
High
Report
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
1/25
07:00 am
pbla
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
High
Report
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum